美罗华联合化疗对老年非霍奇金淋巴瘤效果

THE EFFICACY OF RITUXIMAB COMBINED WITH CHEMOTHERAPY IN THE TREATMENT OF NON-HODGKIN'S MALIGNANT LYMPHOMA IN ELDERLY

目的观察美罗华联合化疗对老年B细胞性非霍奇金淋巴瘤的临床效果和不良反应。方法15例经病理及免疫组化证实的CD20+的B细胞淋巴瘤病人,第1天给予美罗华375 mg/m2,第3天给予CHOP方案化疗,21 d为1个疗程,至少4个疗程。结果总有效率为93.3%,完全缓解66.6%,部分缓解26.7%,稳定6.7%;主要不良反应是胃肠道反应、骨髓抑制、脱发等,少数病人出现畏寒、发热等美罗华输注相关反应。结论美罗华联合化疗治疗老年B细胞性淋巴瘤临床效果好,不良反应可以耐受。

Objective To evaluate the efficacy and toxicity of rituximab combined with chemotherapy in elder patients with B cell non-Hodgkin＇s lymphoma. Methods Fifteen patients with B cell lymphoma of CD20^＋ proved pathologically and immunohistochemically were treated with rituximab 375 mg/m^2 on day 1 and followed by CHOP chemotherapy from day 3. A course of therapy was 21 days, at least four courses were given. Results The total response rate was 93. 3%, complete response 66.6 %, partial response 26.7 %, stable 6.7 %. The main side effects were gastrointestinal reaction, myelosuppression, alopecia. Rituximab-infusing-related chilly and fever occurred in some patients. Conclusion Combination of rituximab and chemotherapy is effective for aged patients with B cell lymphoma, the adverse effects are tolerable.